Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinopharm Partners with ImmBio on Broad-Spectrum Pneumonia Vaccine

publication date: Mar 18, 2019

Sinopharm, the biologics arm of CNBG, partnered with ImmunoBiology (ImmBio), a Cambridge UK vaccine company, to co-develop ImmBio’s novel PnuBioVax vaccine against pneumonia and will be in charge of China commercialization. Sinopharm, which will make multi-million dollar milestone and royalty payments to ImmBio, will manufacture the vaccine for global use. PnuBioVax is designed to be effective against all of the 97 serotypes of the S. pneumoniae bacteria, while present vaccines target between 10 and 23 serotypes. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital